https://www.atjournal.ir/ Advanced Therapies Journal en daily 1 Mon, 01 Dec 2025 00:00:00 +0330 Mon, 01 Dec 2025 00:00:00 +0330 https://www.atjournal.ir/article_235874.html AI and ML are revolutionizing personalized medicine by facilitating predictive, adaptive, and mechanistic treatment planning. Conventional approaches of therapy are, however, rarely tailored on the patient’s molecular and cellular individuality (as well as systemic variability), with suboptimal clinical efficacy and increased toxicity. AI and ML algorithms exploit high-dimensional data—such as genomics, transcriptomics, proteomics, metabolomics, imaging and longitudinal clinical records to discover predictive biomarkers , to optimize the selection of therapy and to deliver interventions in real time. In oncology they are being applied to understand tumour heterogeneity, predict resistance to therapy and develop immunotherapeutic approaches. In gene and cell therapy, ML algorithms drive optimal CAR-T cell production, gRNA selection in CRISPR based therapies, predict cellular persistence and efficacy. It applies in auto-immune, metabolic and cardiovascular diseases for dynamic dosing and monitoring. Challenges consist of data harmonization, model interpretability, applications in clinical workflow, and regulatory adherence. We outline future directions that include multi-modal data fusion, federated learning, explainable AI and reach toward beyond therapeutic modalities. The convergence of AI and ML with molecular medicine has the unprecedented ability to significantly increase precision, effectiveness and safety in advanced therapy applications, providing a paradigm shift toward truly personalized care https://www.atjournal.ir/article_235875.html The incorporation of biomaterials in controlled drug delivery systems has redefined advanced therapeutic modalities through their capability to modulate therapeutic agents with high precision, resulting in improved efficacy and reduced side effects. This survey examines the versatile utility of biomaterials (hydrogels, nanoparticles, and bioactive scaffolds) for advanced therapeutic modalities with a special focus on cellular and molecular responses. We also cover the physicochemical properties, such as biodegradability, biocompatibility, and responsiveness to environmental triggers, which enable them to function as controlled release systems. Clinical and preclinical research highlights these systems as promising platforms in oncology, regenerative medicine, and gene therapies. Nevertheless, obstacles remain in the areas of scaling production, reproducibility, and meeting regulatory requirements. Next steps include the design of multifunctional biomaterials for co-delivery of multiple therapeutic agents, on-line monitoring of drug release, and incorporation with advanced manufacturing technologies toward clinical translation. Moreover, emerging smart biomaterials integrated with real-time sensing and adaptive release mechanisms offer the potential for dynamic, feedback-controlled therapies. Continued integration of biomaterials with digital health, AI-driven modeling, and precision diagnostics will accelerate their path toward personalized and clinically deployable therapeutic systems. https://www.atjournal.ir/article_235877.html Acute and chronic pain continues to cost billions of dollars to society and affects people's functionality and quality of life. Contemporary studies define chronic pain as a complexity of bio-psycho-social-spiritual dimensions. However, clinicians continue to report substantial challenges in delivering balanced and effective pain management. One of the reviewers sought to outline contemporary approaches to pain management, with specific emphasis on pharmacotherapy, novel drugs, and scientifically validated non-pharmacological strategies. In the initial management of pain, the scientifically informed practitioner employs non-opioid analgesics, carefully selected antidepressants, anticonvulsants, and adjunctive biological therapies. The report highlights advances in individualized pain management and precision medicine as a significant paradigm shift in healthcare. In addition, newly researched and reviewed pain-management devices can be used adjunctively to address chronic pain, including advanced neuromodulators and anti-inflammatory biologics. Emerging integrative models that combine digital monitoring, behavioral interventions, and biologically targeted treatments further enhance the potential for personalized and sustainable pain relief. https://www.atjournal.ir/article_235878.html Multiple sclerosis (MS) is a heterogeneous chronic autoimmune disease of the central nervous system that comes with a variety of variants in presentation, progression, and response to treatment. The advent of precision neurology presents a possibility of stratifying diagnosis, prognosis, and treatment options that fit biological personalities. This review examines the existing and developing methods of personalized care in MS in the context of genomic understanding, the discovery of new biomarkers, and pharmacogenomics Genetic variants that affect drug response, pathogenesis, and outcome have been identified using advances in next-generation sequencing and genome-wide association studies. Neuroimaging, cerebrospinal fluid, and blood-based biomarkers have the potential to diagnose earlier, predict disease activity, and monitor treatment with therapeutic efficacy. Pharmacogenomic experiments are playing an increasingly large role in determining patient-specific treatment choice, using these evaluations to optimize efficacy without adversely affecting the patient. The role of such tools in clinical practice has the potential to transform precision neurology as they will offer more specific data-driven treatment opportunities and improve patient outcomes. Questions that have not been answered are the validation of the novel biomarkers, ethical implications of using genomic data, and development of what are sound clinical decision-making algorithms. The aim of this review article is to provide a comprehensive overview of the genetic basis, biomarker-driven strategies, and precision neurology approaches in multiple sclerosis, highlighting current advances, clinical challenges, and future perspectives in personalized therapy. https://www.atjournal.ir/article_235880.html Systemic lupus erythematosus is a chronic autoimmune condition characterized by immunological dysregulation, leading to the production of autoantibodies and subsequent organ dysfunction. The CD154/CD40 signaling pathway is crucial to the pathophysiology of systemic lupus erythematosu, since it facilitates T cell-dependent B cell activation, resulting in the generation of autoreactive B cells and the production of detrimental autoantibodies. Recent breakthroughs in nanotechnology have generated novel options for modulating immune responses in systemic lupus erythematosus, offering potential therapeutic strategies for accurately targeting specific immunological pathways while reducing adverse effects. Nanoparticles (NPs) have emerged as potent instruments in SLE therapy due to their capacity to target immune cells, encapsulate pharmaceuticals, and alter immunological signaling. This review analyzes the utilization of nanoparticles to modulate immune responses in systemic lupus erythematosus, with a particular focus on the CD154/CD40 pathway. We analyze various methodologies, including targeted drug delivery, immune cell modulation, and the induction of immunological tolerance, highlighting key research that has demonstrated the effectiveness of nanoparticles in reducing autoimmune responses and mitigating disease symptoms. Despite promising results in preclinical models, challenges such as biocompatibility, immunogenicity, and scalability remain. The progression of nanoparticle-based therapeutics presents a promising future for enhanced, targeted, and personalized treatments for systemic lupus erythematosus. https://www.atjournal.ir/article_235881.html Chronic inflammation plays a central part in the occurrence and sequential development of cancer. It plays a key role in the initiation of tumors, survival, and metastasis as well as therapeutic resistance. The present paper aims to discuss in detail the compact relationship between inflammatory and cancer processes with focus on how inflammatory processes contribute to the development of cancer and its effects on cancer treatment outcomes. We will examine the molecular mechanisms of inflammation-mediated tumor progression, understand how inflammation modulates metastasis and evaluate its impact in chemotherapy, immunotherapy, and targeted therapies efficacy. Additionally, we are going to explore potential future therapy strategies to target inflammation during cancer therapy application, and how this needs to be specifically modulated to not only increase the effectiveness of the treatment process but also reduce any potential side effects of immune suppression or increased levels of infection. The report concludes with a section devoted to future research directions oriented to the improvement of inflammation-targeted methods to increase the effectiveness of cancer treatments and improve patient outcomes. An increased awareness of the dual role of inflammation in cancer potentially leads to the development of novel and more individualized cancer treatment protocols that could be beneficial to survival and quality of life in the disease.